Fig. 5.

Tumor lysis of engineered T cells against cancer cells. a-b Untransduced, HER2-z, HER2-z-PD-L1–28-engineered T cells were used in co-culture with PD-L1^+/− A549, NCI-H292, SKOV3 or K562-PD-L1 cells at the indicated E:T ratios for 18 h. The results shown are the mean ± SEM for three healthy donors. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 with respect to co-culture with CAR-T cells without the PD-L1 CCR, analyzed using a paired Student’s t-test. c-d Untransduced, HER2-z, HER2-z-PD-L1–28-engineered T cells were used in co-culture with PD-L1⁺ K562 and A549, NCI-H292, or SKOV3 cells at the indicated E:T ratios for 18 h. Each value shown is the mean ± SEM of triplicates